
Rayzon Solar files DRHP with Sebi for Rs 1,500 crore IPO
Tired of too many ads?
Remove Ads
IPO details
Use of proceeds
Capacity growth and manufacturing expansion
Tired of too many ads?
Remove Ads
Product portfolio & clients
Financial Performance
IPO Book Runners and Listing
The company has an installed module manufacturing capacity of 6.00 GW as of March 31, 2025. Rayzon Solar is targeting the next phase of its growth by expanding into solar cell manufacturing The IPO will have a face value of Rs 2 per share and includes a reservation for eligible employees at a discounted rate. The company may also explore a pre-IPO placement of up to Rs 300 crore. If completed, this will reduce the fresh issue size accordingly.Of the planned Rs 1,500 crore IPO, Rs 1,265 crore will be invested in its wholly owned subsidiary, Rayzon Energy Private Limited (REPL), to partially fund the establishment of a 3.5 GW solar cell manufacturing facility using TOPCon (Tunnel Oxide Passivated Contact) technology in Kathvada, Surat. The remainder will be allocated to general corporate purposes.Rayzon began operations in 2017 and scaled its module capacity from 40 MW in 2018 to 6.00 GW by 2025. It currently operates two manufacturing plants in Karanj and Sava, each with 3.00 GW capacity. An additional 2.00 GW capacity at Sava is expected to become operational by October 2025.Through REPL, the company is building a 3.5 GW solar cell unit (operational by FY 2027) and a 19,800 MT aluminium extrusion and anodising unit via another subsidiary, Rayzon Industries, expected to go live in July 2025.The company is a certified manufacturer under the Ministry of New and Renewable Energy's Approved List of Module Manufacturers ('ALMM'), with an enlisted capacity of 3.00 GW, constituting 3.8% of the total ALMM enlisted capacity as of April 21, 2025. (Source: CRISIL Report).Also read: Last chance: HDB Financial's Rs 12,500 crore IPO closes today. Should you chase 8% listing gains? The company offers a wide range of modules, including: Bifacial modules with N-type TOPCon and P-type Mono PERC cells, Monofacial and full black variants with PERC and TOPCon technology,Rayzon serves over 500 clients, including major names like Panasonic Life Solutions, Mahindra Solarize, ACME Cleantech, V-Guard Industries , and Hero Rooftop Energy. It also supplies modules under key government schemes like PM Surya Ghar Muft Bijlee Yojana and PM-KUSUM.As of May 31, 2025, Rayzon had an order book of 3.60 GW for PV modules and a distribution network of 68 channel partners across 59 cities in 20 states and union territories.Rayzon Solar has delivered impreesice growth over the past financial years, with revenue from operations rising from Rs 261.65 crore in FY22 to Rs 1,272.85 crore in FY24, reflecting a CAGR of 120.56%, while EBITDA surged from Rs 13.47 crore to Rs 101.41 crore (CAGR: 174.35%) and profit after tax increased from Rs 3.91 crore to Rs 60.94 crore. For the nine months ended December 31, 2024, the company reported revenue of Rs 1,957 crore and PAT of Rs 239.03 crore.SBI Capital Markets, Ambit Private Limited, and IIFL Capital Services are the book-running lead managers, while KFin Technologies is the registrar. The equity shares will be listed on the BSE and the NSE.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
26 minutes ago
- Economic Times
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.


Economic Times
28 minutes ago
- Economic Times
Nykaa shares rally 5% as brokerages turn more bullish post Q1 results. Should you buy, sell or hold?
Nykaa shares rose 5.4% to Rs 215.95 after brokerages reaffirmed bullish views post-Q1 results. Net profit jumped 79% YoY to Rs 24 crore, revenue grew 23% to Rs 2,155 crore, and GMV climbed 26% to Rs 4,182 crore. Nuvama and JM Financial maintained Buy ratings, citing strong beauty growth, improving fashion performance, and margin expansion potential. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Q1 performance supports outlook Shares of FSN E-Commerce, which operates the Nykaa brand, climbed as much as 5.4% on Wednesday to Rs 215.95 on the BSE after brokerages reaffirmed bullish views and raised price targets following the company's first-quarter maintained its Buy rating on Nykaa with a target price of Rs 235, implying a 15% upside from the stock's last traded price. The brokerage said market share gains remain a strategic priority, with strong momentum in the Beauty & Personal Care segment and improving growth in expects around 20% GMV growth and margin expansion, supported by narrowing losses in the Fashion and eB2B businesses. However, Nuvama trimmed earnings estimates for FY26 and FY27 by 10% and 12%, respectively, due to higher tax assumptions. JM Financial reiterated its Buy call and raised its target price to Rs 260 from Rs 250, implying a potential upside of 27.5% from the last traded brokerage noted that Nykaa delivered robust growth despite a tepid demand environment, with the Beauty & Personal Care vertical posting 26% GMV growth and offline retail rising 33% Financial expects an accelerated improvement in consolidated EBITDA margins, driven by higher profitability in core beauty operations and declining losses in Fashion and reported a 79% year-on-year jump in consolidated net profit to Rs 24 crore for the quarter ended June 30, 2025, on a 23% increase in revenue from operations to Rs 2,155 grew 26% to Rs 4,182 crore, with the Beauty vertical contributing Rs 3,208 crore. EBITDA rose 46% from a year earlier, with margins expanding to 6.5% from 5.5%.The House of Nykaa Beauty business now accounts for 18% of the company's overall beauty GMV, said Falguni Nayar, founder and CEO of Nykaa.'Since our IPO, we have consistently delivered mid-20s growth at a consolidated level. Our cumulative customer base now stands at 45 million, reflecting the growing trust and adoption of our platform,' Nayar added.


Scroll.in
28 minutes ago
- Scroll.in
RPSC ASO application window closes today for 43 posts; here's how to register
The Rajasthan Public Service Commission (RPSC) will close the online application window for the recruitment of Assistant Statistical Officer (Eco. and Stat. Dept.) 2024 posts under Advt. No. 09/2024-25. Eligible candidates can apply for the posts on the official website or The recruitment drive aims to fill up a total of 43 ASO posts. Applicants can check the eligibility criteria, age limit, pay scale, and other details available in the notification below: Here's the official notification. Candidates have to pay a fee of Rs 750 for One Time Registration (OTR). More details in the notification. Steps to register for ASO posts 2024